Medicinal Cannabis Matters: Friday Roundup - 13 March 2026

New Initiative Launches to Support Patients Facing Discrimination

A new initiative called Patient Protect has been launched to support UK medicinal cannabis patients who experience discrimination related to their prescribed treatment.

As reported by Business of Cannabis, the organisation aims to provide guidance and support for patients who encounter difficulties in workplaces, housing or other everyday settings because of their legally prescribed medication. Despite medicinal cannabis being legal in the UK since 2018, many patients still report confusion or misunderstanding from employers, landlords and public services.

Initiatives like this highlight the importance of protecting patient rights while improving public understanding of medicinal cannabis. As more people access treatment through specialist clinics, ensuring that patients feel confident using their medication without stigma or unnecessary barriers remains a key priority.

New Research Explores Cannabis Compound for Chronic Liver Disease

Emerging research is exploring how compounds found in cannabis could potentially support treatment approaches for chronic liver disease.

According to a report from UNILAD, scientists are studying the effects of cannabidiol (CBD) and other cannabinoids on inflammation and liver function. Early findings suggest these compounds may play a role in reducing inflammation and supporting liver health, although further clinical studies will be required to confirm their therapeutic potential.

Research such as this is an important part of expanding the evidence base for medicinal cannabis. While medicinal cannabis is already prescribed for a number of conditions, ongoing scientific investigation continues to explore where cannabinoids may offer additional therapeutic benefits.

The Potential Role of Medicinal Cannabis in the UK’s Mental Health Crisis

A recent article from Leafie examines how medicinal cannabis may play a role in supporting people living with mental health conditions in the UK. With growing pressure on mental health services and long waiting lists for treatment, many patients are exploring alternative or complementary approaches to symptom management.

The article discusses how medicinal cannabis is already being prescribed for conditions such as anxiety, post-traumatic stress disorder and treatment-resistant depression under specialist supervision. While these treatments are not suitable for everyone, they may offer relief for some patients when other therapies have not provided sufficient improvement.

As research develops and clinical experience grows, discussions around medicinal cannabis and mental health are becoming more detailed and evidence-led, with a focus on safe prescribing and appropriate patient assessment.

Medicann Now Stocks Omura Vaporiser Devices

Medicann is pleased to announce that Omura vaporiser devices are now available to patients through our clinics.

The Omura Series X1 Evolution has been designed specifically for medicinal cannabis patients, offering a consistent and controlled vaporisation experience through patented heat-not-burn technology. This method allows patients to use prescribed flower in a way that avoids combustion while maintaining precise temperature control.

Engineered for long-term use, the X1 Evolution features upgraded internal components that have been tested to more than 5,000 heating cycles, making it suitable for regular daily treatment.

You can now access Omura devices through clinic collection in Jersey, Guernsey and the Isle of Man or home delivery across the UK.

If you would like to explore whether medicinal cannabis may be suitable for your condition, you can check your eligibility online in just two minutes using Medicann’s confidential eligibility checker.